Sign Up | Log In | What is SocialPicks?

Oncothyreon Inc (ONTY) Trade Now » Rate ONTY - Discuss ONTY - Add to Watch List

Sector: Healthcare > Industry: Biotechnology & Drugs

SocialPicks Sentiment:

** v.s. other stocks

This Quarter's Sentiment:

All:

100.0%

Top:

100.0%

Rate ONTY:

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

ONTY Analysis & Videos »

... View All >

ONTY: Bull or Bear?

FDA Calendar Updates: EURX, AMGN, FOLD, ONTY, MEDX ONTY

73%

+55.45%
in 164 days

<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...

Continue reading »

By Mike Havrilla (+1.04% risk: conservative) 06/22/09

Comment

Oncothyreon Inc ONTY

62%

+55.45%
in 164 days

<font> <font> <font> ONTY Hits $3.08 A Share Up From Initial June 15th Alert!

June 22, 2009 </font>

</font> </font> <table width="600"> <tbody> <tr> <td width="100%"> <table width="100%"> <tbody> <tr> <td> <font> <> Once again, Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel sy...

Continue reading »

By Marian Filo (-24.55% risk: aggressive) 06/22/09

Comment

New Index of Cancer Diagnostic and Therapeutic Stocks ONTY

73%

+3.41%
in 71 days
(closed on 06/22/09)

By Mike Havrilla on 4/12/09 at BioMedReports.com

The table at the link below includes statistics for the 40 companies in the ETF Innovators Emerging Cancer Diagnostic and Therapeutic Stock Index, which is featured at BioMedReports.com in the health indexes section of the site. The index will track the performance of stocks with market caps below $200M at the inception date of 4/12/09 from a starting value of 2,632.

http://biomedreports.com/articles/most-popular/803-new-index-...

<> A World Health Organization report released last year es...

Continue reading »

By Mike Havrilla (+1.04% risk: conservative) 04/12/09

Comment

Oncothyreon (ONTY) Research Note ONTY

73%

+132.54%
in 25 days
(closed on 04/12/09)

Visit the BioMedReports.com research section to view or download the PDF for Oncothyreon (ONTY) along with other free PDF reports and corporate investor presentations:
http://biomedreports.com/research.html

Oncothyreon : Price: $1.21; Market Cap (MM): $23.6

Market Outperform; Target Price: $4.00

Simos Simeonidis, Ph.D. - Senior Biotech Analyst: Rodman & Renshaw

<> Transferring Coverage. We are assuming coverage of Oncothyreon, a biotechnology company focused on oncology, with a Market Outperform rating and a 12-m...

Continue reading »

By Mike Havrilla (+1.04% risk: conservative) 03/18/09

Comment

... View All >

People Bullish on ONTY

amahmood23

Analyst

N/A

about 1 mo ago

eccentricjunk

Analyst

N/A

2 mos ago

hijack784

Analyst

N/A

3 mos ago

mvpindia

Analyst

N/A

3 mos ago

Mike Havrilla

Principal

73%

5 mos ago

People Bearish on ONTY

... View All >

ROCK-STAR INVESTORS

Rank	Name	Sharpe Ratio	Avg Return	Followers
1	noshoes	21.10	+34.25%	381
2	Gerald Greene	18.14	+72.34%	210
3	stockmarketfunding.com	17.66	+25.65%	55
4	akiralegrand	13.47	+14.32%	62
5	anup2104	12.13	+76.91%	39

... more »

POPULAR STOCKS

Symbol	Company Name	Sentiment
SIRI	Sirius Satellite Radio Inc
V	Visa Inc
XOM	Exxon Mobil Corp
ETFC	E*Trade Financial Corp
MSFT	Microsoft Corp
PFE	Pfizer Inc

... more »

TODAY'S HEADLINES

LDK Solar's Growth Potential Offset by Gross Margin Pressure
by Paul Cheung (Zacks.com) about LDK

Cisco Systems Still a Wait and See
by Thomas Catino (Ant & Sons) about CSCO

The Merrill Lynch Diet: Starving Shareholders
by Zack Miller (BloggingStocks) about MER

Until Housing Improves, Don't Expect Stocks to Rebound
by J.D. Steinhilber (Agile Investing) about SPY

Google Blows Q2: Multiple Compression to Continue
by Henry Blodget about GOOG

... more »

TODAY'S TOP PICKS

DNDN		Cancer Vaccines: Investing Opportunities beyond Dendreon (NASDAQ: D... by Mike Havrilla
CLDA		BioMed Research Reports: Clinical Data (NASDAQ: CLDA), Lpath (OTC: ... by Mike Havrilla
PARD		Biotech Stocks - Beware of The Covered Call Trap by Ivan Mutaftchiev
PBIO		Under the Radar Healthcare Stocks: Protox, Pressure BioSciences, Un... by Mike Havrilla
ISIS		ISIS - Last Tuesday's Drop Presents a Nice Buy Opportunity by Ivan Mutaftchiev

... more »

StreetInsider.com on ONTY

Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover

After-Hours Movers 11/11: COMS, JMBA, GRRF, CTRP, UBET Higher; GMCR, PDC, BZ, ONTY, BRCD, TTEK Lower

Oncothyreon (ONTY) Reports Worse-Than-Expected Q3 Loss of $0.24

Oncothyreon reports third quarter 2009 financial results & provides product pipeline update

Trading Radar for 11/11: Macy's (M), Progressive (PGR), Advanced Auto Parts (AAP), Computer Sciences (CSC) Report

Discussion Wall

+ Add

Be the first to start a discussion and earn 2 points.

... more »

More Resources

About Oncothyreon Inc - Answers.com

Historical Prices - Yahoo

Message Boards - BoardCentral.com

More Info: Yahoo | Google | Reuters

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.